耳鼻咽喉科・頭頸部外科96巻11号

2024年10月発行

特集 頭頸部がん薬物療法—プロに学ぶ最善の選択

《扁平上皮癌に対する薬物療法》

切除不能／再発・転移頭頸部がんに対する治療：殺細胞性抗がん薬を中心に

著者： 山﨑知子¹

所属機関： ¹埼玉医科大学国際医療センター頭頸部腫瘍科

ページ範囲：P.924 - P.928

文献概要

POINT

●頭頸部がんで承認されている薬剤として，殺細胞性抗がん薬ではプラチナ系，フッ化ピリミジン系，タキサン系が，分子標的薬ではEGFR阻害薬であるセツキシマブが，免疫チェックポイント阻害薬では抗PD-1抗体薬であるニボルマブ，ペムブロリズマブが挙げられる。本稿では，殺細胞性抗がん薬を中心にまとめた。

参考文献

1）Kowalski LP, et al：Natural history of untreated head and neck cancer. Eur J Cancer 36：1032-7, 2000

2）Burtness B, et al：Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck（KEYNOTE-048）：a randomised, open-label, phase 3 study. Lancet 394：1915-1928, 2019

3）Ferris RL, et al：Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375：1856-1867, 2016

4）Armand JP, et al：Chemotherapy in head and neck cancer. Eur J Cancer 31A：819-822, 1995

5）Morton RP, et al：Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck：a randomised factorial phase Ⅲ controlled trial. Cancer Chemother Pharmacol 15：283-289, 1985

6）Grose WE, et al：Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region：a Southwest Oncology Group Study. Cancer Treat Rep 69：577-581, 1985

7）Forastiere AA, et al：Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck：a Southwest Oncology Group study. J Clin Oncol 10：1245-1251, 1992

8）Jacobs C, et al：A phase Ⅲ randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10：257-263, 1992

9）Sacco AG, et al：Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. J Clin Oncol 33：3305-3313, 2015

10）Vermorken JB, et al：Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med 359：1116-1127, 2008

11）Mesía R, et al：Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 21：1967-1973, 2010

12）Yoshino T, et al：Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck：results of a phase Ⅱ trial. Jpn J Clin Oncol 43：524-531, 2013

13）Guigay J, et al：Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma（GORTEC 2014-01 TPExtreme）：a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 22：463-475, 2021

14）Tahara M, et al：Phase Ⅱ trial of combination treatment with paclitaxel, carboplatin and cetuximab（PCE）as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck（CSPOR-HN02）. Ann Oncol 29：1004-1009, 2018

15）Vermorken JB, et al：Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck（SPECTRUM）：an open-label phase 3 randomised trial. Lancet Oncol 14：697-710, 2013

16）Hitt R, et al：Phase Ⅱ study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 23：1016-1022, 2012

17）Rubió-Casadevall J, et al：TTCC-2019-02：real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol 13：1226939, 2023

18）Del Barco Morillo E, et al：Phase Ⅱ study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study. Oral Oncol 62：54-59, 2016

19）Lin JT, et al：Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer. Adv Ther 29：71-77, 2012

20）Cho H, et al：Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. Auris Nasus Larynx 42：396-400, 2015

21）Szturz P, et al：Management of recurrent and metastatic oral cavity cancer：Raising the bar a step higher. Oral Oncol 101：104492, 2020

22）Machiels JP, et al：Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy（LUX-Head & Neck 1）：an open-label, randomised phase 3 trial. Lancet Oncol 16：583-594, 2015

23）Markman M, et al：Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9：389-393, 1991

24）Seiwert TY, et al：A randomized, phase Ⅱ study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 25：1813-1820, 2014

25）犬山征夫：進行・再発頭頸部癌患者に対するS-1の後期臨床第Ⅱ相試験—多施設共同研究．癌と化療28：1381-1390，2001

26）犬山征夫：頭頸部癌に対するCisplatinのphase Ⅱ study．癌と化療13：232-238，1986

27）Vermorken JB, et al：Open-label, uncontrolled, multicenter phase Ⅱ study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25：2171-2177, 2007